Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00815919 · ClinicalTrials.gov registry record · Phase 2
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00815919 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 22 participants.
The verdict
NCT00815919, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the effectiveness of bortezomib (Velcade) plus prednisone for treating chronic graft versus host disease (cGVHD) and the safety of this drug combination in this patient population. Chronic GVHD is a medical condition that may occur after allogeneic stem cell transplantation. The donor's immune system may recognize the participants body (the host) as foreign and attempt to "reject" it. Bortezomib has been used in other research studies, and information from those studies suggests that this drug may help to control the abnormal immune responses that underlie cGVHD.
Interventions
- DRUG Prednisone
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00815919
The ClinicalTrials.gov registry entry for NCT00815919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT00815919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00815919 about?
NCT00815919 is a clinical study titled "Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease". The purpose of this research study is to determine the effectiveness of bortezomib (Velcade) plus prednisone for treating chronic graft versus host disease (cGVHD) and the safety of this drug combination in this patient population. Chronic GVHD is a medical condition that may occur after allogeneic ...
What is the current status of trial NCT00815919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2008-12. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00815919?
The interventions under investigation include: Prednisone (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00815919?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.